Search

Displaying results 2051 - 2060 of 4207 in total
  1. Drug

    Von Willebrand factor human

    go.drugbank.com/drugs/DB13133
    ApprovedInvestigational

    It was first approved by the FDA in 2015. … It serves a dual role in hemostasis by mediating platelet adhesion and aggregation at the site of blood vessel injury and stabilizing procoagulant factor VIII (FVIII).

  2. Drug

    Tofersen

    go.drugbank.com/drugs/DB14782
    ApprovedInvestigational

    [L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.

  3. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses.

  4. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients 12 years and older to be approved by

  5. Drug

    Ranpirnase

    go.drugbank.com/drugs/DB04950
    Investigational

    It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.

  6. Drug

    Fezolinetant

    go.drugbank.com/drugs/DB15669
    ApprovedInvestigational

    [A259542] Fezolinetant was approved by the FDA in May 2023 under the brand name Veozah.[L46422] It was subsequently approved by the EMA in December 2023 for the same indication.[L50086] … [A259591,A259542] By antagonizing NK3 receptors, neuronal signalling can be dampened to reduce VMS.

  7. Drug

    Emtricitabine

    go.drugbank.com/drugs/DB00879
    ApprovedInvestigational

    [L9019] The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.[L9019] Emtricitabine was granted FDA approval on 2 July 2003.[L9019]

  8. Drug

    Ixabepilone

    go.drugbank.com/drugs/DB04845
    ApprovedInvestigational

    Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug.

  9. Drug

    1,2-dichlorobenzene

    go.drugbank.com/drugs/DB13963
    ApprovedWithdrawn

    This derivative of benzene differs from the parent compound by the presence of two adjacent chlorine atoms. 1,2-dichlorobenzene is used as a precursor for agrochemicals, as a solvent for fullerenes, as

  10. Drug

    Calaspargase pegol

    go.drugbank.com/drugs/DB14730
    ApprovedInvestigational

    Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890].